Westshore Wealth LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Westshore Wealth LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,932 shares of the biopharmaceutical company’s stock, valued at approximately $320,000.

Other large investors also recently bought and sold shares of the company. TRUE Private Wealth Advisors acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $25,000. Pin Oak Investment Advisors Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $26,000. IndexIQ Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $28,000. TFO TDC LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $29,000. Finally, Engrave Wealth Partners LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 80.32% of the company’s stock.

In other news, EVP Brett A. Pletcher sold 2,950 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $64.63, for a total value of $190,658.50. Following the sale, the executive vice president now directly owns 20,014 shares of the company’s stock, valued at approximately $1,293,504.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Olsen Per Wold sold 20,282 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $69.00, for a total transaction of $1,399,458.00. Following the sale, the director now directly owns 119,574 shares in the company, valued at $8,250,606. The disclosure for this sale can be found here. Insiders sold a total of 73,532 shares of company stock valued at $5,101,386 over the last 90 days. Company insiders own 0.20% of the company’s stock.

GILD has been the subject of a number of analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, February 5th. Piper Sandler raised shares of Gilead Sciences from a “neutral” rating to an “overweight” rating and raised their price target for the company from $70.00 to $90.00 in a research report on Friday, March 20th. Guggenheim lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 21st. Bank of America raised their price target on shares of Gilead Sciences from $70.00 to $72.00 and gave the company a “neutral” rating in a research report on Wednesday, February 5th. Finally, HC Wainwright lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating in a research report on Monday, March 2nd. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $77.69.

GILD stock traded down $1.36 during midday trading on Tuesday, reaching $74.57. The company had a trading volume of 7,072,177 shares, compared to its average volume of 27,712,346. The company has a debt-to-equity ratio of 1.02, a current ratio of 3.10 and a quick ratio of 3.01. Gilead Sciences, Inc. has a 1 year low of $60.89 and a 1 year high of $85.97. The company has a market capitalization of $93.76 billion, a P/E ratio of 17.71, a P/E/G ratio of 5.70 and a beta of 0.99. The firm has a 50-day moving average price of $71.74 and a 200-day moving average price of $66.72.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.37). Gilead Sciences had a net margin of 23.99% and a return on equity of 35.49%. The business had revenue of $5.88 billion during the quarter, compared to analysts’ expectations of $5.74 billion. During the same period last year, the company posted $1.44 EPS. Gilead Sciences’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.03 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a $0.68 dividend. The ex-dividend date was Thursday, March 12th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.63. This represents a $2.72 annualized dividend and a yield of 3.65%. Gilead Sciences’s dividend payout ratio is 44.30%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Forex

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.